Suffering

Author Anthony Green's new book "Pick Up Your Own Damn Crutch!" is a stirring source of motivation in getting through life's seemingly infinite trials

Retrieved on: 
Tuesday, January 12, 2021
Articles, Branches of biology, Emotions, Suffering, Loneliness, Philosophy of love, Hope, Mental disorder, Pain

I have written this book, Pick Up Your Own Damn Crutch, for several reasons.

Key Points: 
  • I have written this book, Pick Up Your Own Damn Crutch, for several reasons.
  • It helps me work out mentally, the trials I have been through, allowing me to put in perspective regarding my life.
  • I also hope my story will help others deal with their life trials, whether it is surgery/pain, mental illness/depression, or relationship/loneliness.
  • Life can be more joyous if you respect others for who they are and care for their needs.

Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference

Retrieved on: 
Thursday, January 7, 2021
Psychiatry, Branches of biology, Mind, Abnormal psychology, Psychiatric diagnosis, Psychopathology, Mental disorder, Psychiatric assessment, Suffering

A live audio webcast of the ICR Westwicke Conference presentation will be available online at the investor relations page of the Companys website at ir.neuronetics.com.

Key Points: 
  • A live audio webcast of the ICR Westwicke Conference presentation will be available online at the investor relations page of the Companys website at ir.neuronetics.com.
  • A replay of the webcast will be archived on the website for approximately 90 days.
  • Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.
  • NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japans national health insurance.

IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Clinical medicine, Nervous system, Acute pain, Nociception, Pain, Suffering, Sjögren syndrome

"With this agreement, IACTA and Pharmaleads willcollaborate to develop next-generation pain treatments to help themillions of people across the globe living with the debilitating effects of ocular pain," saidDamon Burrows, CEO of IACTA.

Key Points: 
  • "With this agreement, IACTA and Pharmaleads willcollaborate to develop next-generation pain treatments to help themillions of people across the globe living with the debilitating effects of ocular pain," saidDamon Burrows, CEO of IACTA.
  • "We believe that the epithelial protective properties of DENKI observed in preclinical studies, combined with its pain-relieving properties will revolutionize eye care."
  • Pharmaleads and Pharmaleads Greater China will together be eligible to receive up to $100M in total deal value including upfront, development, regulatory, and commercial milestone payments.
  • Based on the ocular preclinical package already available and human systemic safety data, IACTA expects to start human proof of concept trials in ocular pain in 2021.

Global Cancer Pain Pipeline Review, H2 2020 Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 31, 2020
Pharmaceutical, Health, Oncology, Clinical trials, Nervous system, Branches of biology, Acute pain, Nociception, Pain, Suffering, Cancer, Pipeline

The "Cancer Pain - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Pain - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Cancer Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Global Mental Disorder Treatment Market to Surpass US$ 75.7 Billion by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Thursday, December 24, 2020
Marketing, Mental health, Communications, Health, FDA, Pharmaceutical, Psychiatry, Psychiatric diagnosis, Psychopathology, Abnormal psychology, Psychology, Psychiatric assessment, Mind, Mental disorder, Suffering, Allergan, Prevalence of mental disorders

According to Coherent Market Insights, the global mental disorder treatment market is estimated to be valued at US$ 48.4 billion in 2020 and is expected to exhibit a CAGR of 6.6 % during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global mental disorder treatment market is estimated to be valued at US$ 48.4 billion in 2020 and is expected to exhibit a CAGR of 6.6 % during the forecast period (2020-2027).
  • Key companies are focusing on product approvals from regulatory bodies to develop treatment for mental disorders is expected to propel growth of the global mental disorder treatment market during the forecast period.
  • The global mental disorder treatment market is expected to exhibit a CAGR of 6.6% during the forecast period, owing to rising prevalence of mental disorders globally.
  • Key players operating in the global mental disorder treatment market include Allergan plc.

Karuna Therapeutics Appoints Denice Torres, J.D., to its Board of Directors

Retrieved on: 
Tuesday, December 22, 2020
Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Psychiatry, Articles, Mind, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychiatric diagnosis, Psychopathology, Suffering, Torres, Psychological resilience, Neuropsychiatry

Im truly pleased to join Karunas board, particularly during this important inflection point for the company, said Ms. Torres.

Key Points: 
  • Im truly pleased to join Karunas board, particularly during this important inflection point for the company, said Ms. Torres.
  • The most successful organizations are those that are not only purpose-driven, but also leverage multidimensional thinking.
  • Karuna exemplifies these qualities through their innovative approach to drug development, and their passionate team driven to deliver non-incremental advances in treatments for those living with severe neuropsychiatric disorders.
  • Ms. Torres serves on the Board of Directors of bluebird bio and National Resilience, Inc. She holds a B.S.

COVID-19 Boosts Montfort's Remote Neurological Monitor

Retrieved on: 
Wednesday, December 16, 2020
Psychiatry, Psychiatric diagnosis, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychopathology, Suffering, Neurology, Psychology, Mind

BINYAMINA, Israel, Dec. 16, 2020 /PRNewswire/ --Montfort ( Mon4t ), an innovative medical startup introduces its real-time, remote neurological monitor.

Key Points: 
  • BINYAMINA, Israel, Dec. 16, 2020 /PRNewswire/ --Montfort ( Mon4t ), an innovative medical startup introduces its real-time, remote neurological monitor.
  • "About one billion people around the world suffer from neurological and psychiatric disorders.
  • Moreover, many countries are starting to reimburse remote monitoring costs, which adds a strong economic incentive for tele-medicine.
  • Our App allows standard neurological examination to be conducted anytime, anywhere, by using a standard smartphone," says Dr. Yekutieli.

OneRecord and Suffering the Silence Team Up

Retrieved on: 
Tuesday, December 15, 2020
Articles, Blumenthal, Films, Silence, Suffering, Creative works

Jennifer Blumenthal, Co-Founder and CEO of OneRecord , first met Allie Cashel, Co-Founder of Suffering the Silence , in 2017.

Key Points: 
  • Jennifer Blumenthal, Co-Founder and CEO of OneRecord , first met Allie Cashel, Co-Founder of Suffering the Silence , in 2017.
  • "It's also important for other patients who are suffering to hear these stories and know they can be supported.
  • Both of our organizations can work together to spread the message that suffering in silence is too common -- going at it alone and without the right [support] shouldn't be normal."
  • "Joining with Suffering the Silence keeps us rooted in the reason we started OneRecord -- to give patients the tools to advocate for themselves," states Blumenthal.

Global Low Back Pain Pipeline Review, H2 2020 Featuring 33 Key Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Pharmaceutical, Health, Physical therapy, Branches of biology, Nervous system, Anatomy, Acute pain, Nociception, Pain, Suffering, Low back pain

Low Back Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Low Back Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

Kosi Radio Voice is Cracking the Jesus Code Discovering the Secret Teaching of the Virgin Birth

Retrieved on: 
Wednesday, December 9, 2020
Articles, Religion, Canonical Gospels, Christology, Jesus in Christianity, Jesus, Suffering

What if the birth of Jesus is the dawn of an evolutionary consciousness that is more relevant now than it was over two thousand years ago?

Key Points: 
  • What if the birth of Jesus is the dawn of an evolutionary consciousness that is more relevant now than it was over two thousand years ago?
  • What if there is a secret message contained within this story with the power to end eons of suffering?
  • What if the virgin birth is actually a living presence pregnant with the great secret of eternal life?
  • The heartbreaking reality of this corruption is it locked Jesus in a prison of dogma, despair, cynicism, and suspicion.